ACE2

Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19

Sunday, September 19, 2021 - 12:29pm

The pseudovirus and authentic virus studies demonstrated that the Therapy retains neutralization activity against the Alpha and Delta variants.

Key Points: 
  • The pseudovirus and authentic virus studies demonstrated that the Therapy retains neutralization activity against the Alpha and Delta variants.
  • Lilly licensed etesevimab from Junshi Biosciences after it was jointly developed by Junshi Biosciences and the Institute of Microbiology of the Chinese Academy of Sciences.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

DGAP-News: Formycon's COVID-19 drug FYB207 Wins Prestigious Pharma Trend Image & Innovation Award 2021

Wednesday, September 15, 2021 - 8:01am

Press Release // September 15, 2021

Key Points: 
  • Press Release // September 15, 2021
    Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) yesterday received the Pharma Trend Image & Innovation "Most Innovative Product(R)" Award in the category of Leap Innovations for its COVID-19 drug development FYB207.
  • For what is now the 22nd time, the Pharma Trend Image & Innovation Awards, also known in the industry as the Pharma Oscars, were presented in various categories at a celebratory awards ceremony under the patronage of Bavarian Health Minister Klaus Holetschek, MdL.
  • "Receiving the prestigious Pharma Trend Image & Innovation 'Most Innovative Product(R)' Award for Leap Innovations is a great pleasure and encourages us in our innovative COVID-19 drug development.
  • Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug.

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021

Monday, September 13, 2021 - 2:00pm

SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C.Wainwright 23rd Global Investment Conference ( www.hcwevents.com/annualconference ).

Key Points: 
  • SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C.Wainwright 23rd Global Investment Conference ( www.hcwevents.com/annualconference ).
  • Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization.
  • COVI-AMG (STI-2020): Potentially highly potent/low dose antibody in a 2 minute IV-push in Phase 2 trials for systemic treatment in an outpatient setting.
  • Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.

Bayer Announces Recipients of the Second Annual Pulmonary Hypertension Accelerated Awards

Friday, September 10, 2021 - 1:00pm

Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).

Key Points: 
  • Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based research grant program created to support clinical research in pulmonary hypertension (PH), with a focus on pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
  • The PHAB Awards in recognizing the dedicated efforts of worthy researchers, underscores Bayers commitment to health for all.
  • Samuel Rayner, M.D., University of Washington Center for Lung Biology, to study proximal pulmonary vascular compliance and inflammation in PAH.
  • Our online press service is just a click away: www.bayer.us/en/newsroom
    BAYER and the Bayer Cross are registered trademarks of Bayer.

GemPharmatech Presents Humanized Mouse Models to Support Bispecific Antibody and COVID-19 Preclinic Development at Biologics UK Oxford Global Conference

Thursday, September 9, 2021 - 1:00pm

GemPharmatech (GemPharmatech Co., Ltd. GPT ) presented its humanized mouse models to support T-Cell Bispecific antibody and COVID-19 preclinic development and co-hosted a panel discussion on bispecific antibodies at Biologics UK Oxford Global Conference, London, UK, Sept. 6-8, 2021.

Key Points: 
  • GemPharmatech (GemPharmatech Co., Ltd. GPT ) presented its humanized mouse models to support T-Cell Bispecific antibody and COVID-19 preclinic development and co-hosted a panel discussion on bispecific antibodies at Biologics UK Oxford Global Conference, London, UK, Sept. 6-8, 2021.
  • As the potential applications of biologics continue to grow, so does the need for the proper animal models to use for preclinical studies.
  • GemPharmatech is a leading global provider of animal models and services, especially in generating genetically engineered mouse models for preclinical research and development.
  • GemPharmatech, Co., Ltd. ( GPT ) is a leading provider in animal models and services, especially in the development of humanized animal models, to global Pre-Clinical R&D Communities.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Wednesday, September 1, 2021 - 8:00am

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Wednesday, September 1, 2021 - 8:00am

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

Kintor Pharma Announces 2021 Interim Results

Monday, August 30, 2021 - 2:46am

SUZHOU, CHINA, Aug 30, 2021 - (ACN Newswire) - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.

Key Points: 
  • SUZHOU, CHINA, Aug 30, 2021 - (ACN Newswire) - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced its 2021 interim results and released an update on its recent progress in clinical development, commercialization (including license-out and production capacity expansion), and activities in Hong Kong capital market.
  • Dr.Youzhi Tong, Founder, Chairman, and CEO of Kintor Pharma, commented,
    "In the first half of 2021, Kintor Pharma has made great progress in areas including research, clinical operations, and business cooperation with reputable partners.
  • In 2021, Kintor Pharma received greenlight from the U.S. Food and Drug Administration (FDA) and the approval from Brazilian Health Regulatory Agency (ANVISA) to conduct phase III clinical trials with proxalutamide in patients with COVID-19.
  • Meanwhile, Kintor Pharma is working on designing clinical trials for combination therapy of ALK-1/VEGF dual-targeting antibody for solid tumor types.

Distribution of Etesevimab/JS016 in the US Reopened

Sunday, August 29, 2021 - 1:03pm

The decision to resume distribution aligns with the FDAs issuance of an updated fact sheet (the Fact Sheet) and a revised letter of authorization for etesevimab and bamlanivimab together.

Key Points: 
  • The decision to resume distribution aligns with the FDAs issuance of an updated fact sheet (the Fact Sheet) and a revised letter of authorization for etesevimab and bamlanivimab together.
  • Over the last several months, prevalence of variants varies by state, region and even country and can change rapidly.
  • Founded in December 2012, Junshi Biosciences is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China.

NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies

Thursday, August 26, 2021 - 11:48am

This partnership creates an efficient and highly flexible logistics and distribution model for NRx.

Key Points: 
  • This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • "This partnership creates an efficient and highly flexible logistics and distribution model for NRx.
  • Cardinal Health Specialty Pharmaceutical Distribution will serve as the exclusive distributor for ZYESAMI, providing broad access to hospitals for this needed medicine upon FDA authorization.
  • "Cardinal Health is pleased to ensure that COVID-19 patients get access to treatment in a timely and efficient manner."